Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2002
10/31/2002WO2002085336A1 Orodispersible effervescent tablets
10/31/2002WO2002085311A2 Hcg formulation
10/31/2002WO2002085301A2 Indole, azaindole and related heterocyclic amidopiperazine derivatives
10/31/2002WO2002085291A2 Nociceptin analogs
10/31/2002WO2002071062A8 Diagnosis and treatment of inflammation and hyperactive immune conditions
10/31/2002WO2002068390A8 Diamides which inhibit tryptase and factor xa activity
10/31/2002WO2002068381A3 Aryl-n-cyanoguanidines and methods related thereto
10/31/2002WO2002064161A9 Method and compositions for immunization with the pseudomonas v antigen
10/31/2002WO2002061105A9 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
10/31/2002WO2002060949A3 Glycoforms a fas ligand inhibitory protein analog
10/31/2002WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002WO2002042489A9 Methods involving a t cell protein tyrosine phosphatase
10/31/2002WO2002041896A3 Use of thienopyrimidines
10/31/2002WO2002024912A3 Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof
10/31/2002WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002WO2002020045A3 Vaccine against microbial pathogens
10/31/2002WO2002014499A3 Claudin polypeptides
10/31/2002WO2002012502A3 Anti-tnf antibodies, compositions, methods and uses
10/31/2002WO2002008434A3 Bicistronic influenza comprising two genes in tandem
10/31/2002WO2002004002A3 Use of strains of the parapox ovis virus for producing antiviral pharmaceuticals and anticancer pharmaceuticals
10/31/2002WO2001060156A9 Neutralizing antibody and immunomodulatory enhancing compositions
10/31/2002WO2001056601A9 Low dose haptenized tumor cell and tumor cell extract immunotherapy
10/31/2002WO2001051633A9 Compositions and methods for the therapy and diagnosis of prostate cancer
10/31/2002WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002US20020162129 Prevention and treatment of alzheimer's disease
10/31/2002US20020161262 Use treating various medical conditions, including pain
10/31/2002US20020161237 (Z)-2-((2-bromo-4-(((3-hydroxybenzyl)amino)carbonyl)benzoyl) -amino)pent-2-enoic acid, for example; useful for treating psoriasis
10/31/2002US20020161221 Ether type lipid a 1-carboxylic acid analogs
10/31/2002US20020161054 And treatment of Chronic Obstructive Pulmonary Disease and allergic rhinitis
10/31/2002US20020161053 Inflammatory cytokine production inhibitors, matrix metalloprotease production inhibitors, inflammatory cell adhesion molecules incidence inhibitors, antiinflammatory agents
10/31/2002US20020161038 Inosine 5'-monophosphate dehydrogenase (IMPDH); prodrug having functional group -CO-N(-R)-COO-, a carrier, and an immunosuppressant, anticancer agent, antiviral agent, or anti-vascular hyperproliferation agent
10/31/2002US20020161033 Substituted 1,5-dihydropyrrol-2-one derivatives active as NMDA receptor antagonists for treatment of states of pain
10/31/2002US20020161025 N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action
10/31/2002US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002US20020161014 Purinyl substituted quinazoline-4-one derivatives
10/31/2002US20020161006 1,4-dihydropyridine compounds as bradykinin antagonists
10/31/2002US20020161005 Nitrogen heterocycle compounds
10/31/2002US20020160999 Treatment of diseases or disorders of the central nervous system
10/31/2002US20020160987 Novel 4-dedimethylaminotetracycline derivatives
10/31/2002US20020160984 For example, 2,3-dihydro-1H-benz(de)isoquinolin-1-one; treating diabetes, cancer, radiosensitizing tumor cells, cardiovascular disorders, septic shock, inflammatory bowel disease, senescent cells
10/31/2002US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002US20020160965 Cosmetic and dermatological formulations comprising flavonoids
10/31/2002US20020160964 Conjugates comprising galactose alpha 1,3 galactosyl epitopes and methods of using same
10/31/2002US20020160948 Such as preventing or treating primary cancer cell growth
10/31/2002US20020160947 Synergistic method for prolonging allograft survival
10/31/2002US20020160943 Tumor-activated prodrug compounds and treatment
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160481 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
10/31/2002US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002US20020160027 Conjugate, its preparation and use
10/31/2002US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002US20020160012 Vaccine chip technology exploiting immunostimulating fragment of TGF-BETA
10/31/2002US20020160010 Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
10/31/2002US20020160003 Antibody antagonists of VE-cadherin without adverse effects on vascular permeability
10/31/2002US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002US20020159999 Administering donor peripheral blood progenitor cells to recipient and administering a non-chronic course of an immunosuppressant, e.g., cyclosporine
10/31/2002US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002US20020159974 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159973 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159971 Methods and compositions for preventing and treating neutrophil-mediated diseases
10/31/2002US20020159969 A MUC-1 mucin (a high molecular weight glycoprotein) derivative, containing specific amino acid sequence and less than 60 amino acid in length, linked to a cytokine; clinically significant marker for cancers
10/31/2002DE10121113A1 Genmodifizierte YT Zelllinie und ihre Verwendung Genetically Modified YT cell line and their use
10/31/2002CA2445255A1 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002CA2445233A1 Phthalazinones derivatives useful as pde4/7 inhibitors
10/31/2002CA2445202A1 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls
10/31/2002CA2445188A1 Arylindenopyridines with pde inhibiting activity
10/31/2002CA2444883A1 Microprojection array having a beneficial agent containing coating
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444370A1 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002CA2444235A1 New polynucleotides and polypeptides of the ifn.alpha.-17 gene
10/31/2002CA2443600A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002CA2439690A1 Modified interferon alpha with reduced immunogenicity
10/31/2002CA2438833A1 Lactic acid bacteria as agents for treating and preventing allergy
10/30/2002EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002EP1252323A2 Virus strains for the oncolytic treatment of cancer
10/30/2002EP1252322A2 Herpes virus strains for gene therapy
10/30/2002EP1252307A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
10/30/2002EP1252298A2 Phosphodiesterases
10/30/2002EP1252296A1 Method and system for determining parameters of a protocol for deferred use of immunocompetent cells
10/30/2002EP1252188A2 G-protein coupled receptors
10/30/2002EP1252164A1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid
10/30/2002EP1252163A2 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
10/30/2002EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002EP1252155A1 Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
10/30/2002EP1252154A1 Heterocyclic amide derivatives
10/30/2002EP1252153A1 Substituted piperidines, medicaments containing these compounds, and methods for the production thereof
10/30/2002EP1252152A1 Urea compounds as inhibitors for vla-4
10/30/2002EP1252144A1 Substituted glutarimides and use thereof il-12 production inhibitors
10/30/2002EP1252143A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives
10/30/2002EP1252133A2 Pharmaceutical compounds
10/30/2002EP1251873A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
10/30/2002EP1251871A1 Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
10/30/2002EP1251864A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
10/30/2002EP1251852A1 Use of desloratadine for treating allergic and inflammatory conditions
10/30/2002EP1251851A1 Treating allergic and inflammatory conditions
10/30/2002EP1251841A1 Aqueous solution for treating degenerative or autoimmune diseases and as immunomodulatory agent
10/30/2002EP1251835A2 Closure of bacterial ghosts
10/30/2002EP1251829A1 Electrospun pharmaceutical compositions
1 ... 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 ... 1172